Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Cuts Jobs And Pushes Oncology After Patent Losses Nudge 2009 Sales Down 4.7%

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda continues to see the negative impact of patent loss on key products sold in North America, and coupling that with the strong yen against the U.S. dollar and other currencies, the company reported May 13 revenue decreases of a sharp 4.7 percent in fiscal 2009 - its first sales decline in 19 years
Advertisement

Related Content

Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off
Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off
Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership
Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership
Takeda Takes Global Expansion Next Door To South Korea
Takeda Takes Global Expansion Next Door To South Korea
Japan Adds 12 Drugs To NHI Price List; Takeda Takes Four, Pfizer, Alexion Also Gain
Japan Adds 12 Drugs To NHI Price List; Takeda Takes Four, Pfizer, Alexion Also Gain
Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)
Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
Advertisement
UsernamePublicRestriction

Register

SC074818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel